Sun Pharma Unveils Breakthrough Dermatology Data, Promising Enhanced Patient Care

DENVER, CO – March 27, 2026 – Global pharmaceutical giant Sun Pharma today presented a significant body of new research at the 2026 American Academy of Dermatology (AAD) Annual Meeting, signaling major advancements in the treatment of psoriasis, alopecia areata, and acne. The company's showcase of 14 scientific abstracts highlights the sustained effectiveness and innovative mechanisms of its leading dermatology drugs—ILUMYA®, LEQSELVI™, and WINLEVI®—reinforcing its commitment to addressing the unmet needs of millions living with chronic and often debilitating skin conditions.

The data, spanning pivotal clinical trials and real-world evidence, underscores a strategy focused not only on clearing skin or regrowing hair but on improving long-term outcomes and overall quality of life. "The data we are presenting at AAD underscore our commitment to advancing dermatology and immunology through meaningful science – spanning not only clinical efficacy and safety, but also how these therapies perform over time and in real-world practice," said Ahmad Naim, MD, Senior Vice President and North American Chief Medical Officer at Sun Pharma. "Behind every data point is a person, and our responsibility is to continue investment in science that translates into clinically meaningful outcomes for people living with these chronic conditions."

Transforming Patient Outcomes from Psoriasis to Hair Loss

For patients, the latest findings translate into tangible hope. New data for ILUMYA® (tildrakizumab-asmn) demonstrated sustained efficacy and safety over 52 weeks in patients with moderate-to-severe psoriasis affecting the nails—a notoriously difficult-to-treat manifestation of the disease. This is a crucial development, as nail psoriasis can cause significant pain and social stigma. The results, from a dedicated Phase 3b trial, showed that over 41% of patients achieved at least 75% improvement in their nail psoriasis by the end of one year, offering a durable solution for a persistent problem.

Perhaps the most dramatic results came from the alopecia areata portfolio. Pooled data from the THRIVE-AA1 and THRIVE-AA2 pivotal trials for LEQSELVI™ (deuruxolitinib) revealed that patients with severe alopecia areata experienced significant scalp hair regrowth as early as eight weeks into treatment, with continued improvement over time. For a condition characterized by sudden and extensive hair loss, the speed of this response is a game-changer, potentially mitigating some of the profound psychological distress, including anxiety and depression, that affects up to 2.5% of the population who experience the disease in their lifetime.

Further illuminating the patient experience, Sun Pharma presented a landmark survey that exposed a meaningful gap between how clinicians and patients perceive alopecia areata. The findings suggest that clinicians may underestimate the emotional burden of moderate hair loss, while patients prioritize safety and shared decision-making alongside rapid regrowth. This underscores the need for better communication and highlights how effective treatments like LEQSELVI can empower patients in discussions about their care goals.

In the realm of acne, a 52-week study on WINLEVI® (clascoterone cream 1%) showed a significant and progressive reduction in both facial oil (sebum) production and acne severity. As the first-in-class topical androgen receptor inhibitor, WINLEVI targets a key hormonal driver of acne. New pilot studies also suggest its effectiveness in combination with other common acne therapies, potentially broadening its use and providing dermatologists with a versatile new tool for creating multimodal treatment plans for the millions of adolescents and adults affected by acne.

Solidifying Leadership in a Competitive Market

The data presented at AAD 2026 is not just a win for patients; it's a strategic masterstroke for Sun Pharma, solidifying its leadership in the fiercely competitive dermatology market. Each data set strengthens the competitive moat around its key products.

In the crowded psoriasis space, ILUMYA, an IL-23 inhibitor, faces rivals like AbbVie's Skyrizi and Janssen's Tremfya. By providing robust, long-term data on a challenging indication like nail psoriasis and backing it with real-world evidence of effectiveness across diverse populations, Sun Pharma carves out a durable niche for ILUMYA as a reliable and holistic treatment option.

For alopecia areata, the oral JAK inhibitor class is the new frontier. LEQSELVI competes with other approved treatments like Olumiant and Litfulo. The emphasis on early hair regrowth as soon as eight weeks provides a powerful and easily communicated differentiator for both clinicians and patients anxious for visible results. This head-start in efficacy could prove decisive in capturing market share.

Meanwhile, WINLEVI continues to define its own market. As the first topical to directly block androgen receptors in the skin, it has a unique mechanism. The new data on long-term sebum reduction and, crucially, its successful use in combination therapies, expands its utility beyond a niche product. It positions WINLEVI as a foundational element in modern acne care, capable of being integrated into regimens for a broad spectrum of patients, including males for whom topical hormonal treatments were not previously an option.

Unpacking the Science Behind the Breakthroughs

Underpinning these clinical successes is a foundation of targeted science. Each of Sun Pharma's highlighted drugs works on a distinct and innovative pathway, representing a shift toward more precise dermatological therapies.

ILUMYA's efficacy stems from its selective targeting of the p19 subunit of interleukin-23 (IL-23), a key cytokine that drives the inflammatory cascade in psoriasis. By inhibiting this specific pathway, it effectively quiets the overactive immune response that causes psoriatic plaques and nail damage, with a favorable long-term safety profile.

LEQSELVI is an oral inhibitor of Janus kinases JAK1 and JAK2. These enzymes are crucial signaling messengers within immune cells that, in alopecia areata, mistakenly command an attack on hair follicles. By blocking these signals, LEQSELVI effectively shields the follicles from the autoimmune assault, allowing for the resumption of normal hair growth. The THRIVE-AA pivotal trials, which enrolled over 1,200 patients, rigorously demonstrated this effect, with about a third of patients achieving at least 80% scalp coverage after 24 weeks.

WINLEVI's innovation lies in its topical application and targeted action. It competes with androgens for binding to receptors in the skin's sebaceous glands. This localized blockade reduces the hormonal signals that trigger excess sebum production and inflammation—two primary causes of acne. The 52-week study confirms that this effect is not only significant but also progressive, and its chemical stability allows it to be layered with other treatments, a practical advantage that simplifies complex acne regimens for patients.

Collectively, the data from Sun Pharma at AAD 2026 paints a picture of a company deeply invested in the science of dermatology, translating complex immunology into practical, life-changing solutions that offer not just treatment, but a renewed sense of normalcy for patients worldwide.